Aura Biosciences Inc (AURA)

Over the past six months, Aura Biosciences' stock price has fluctuated, with a 52-week high of $7.48 on July 27, 2025, and a 52-week low of $4.35 on May 14, 2025. As of early April 2026, the stock price was around $6.54 to $6.80. On March 30, 2026, the company reported its Fourth Quarter and Full Year 2025 financial results, announcing accelerated enrollment in its Phase 3 CoMpass trial and expected initial data from its Phase 1b/2 NMIBC trial, which led to a slight stock decline. On March 31, 2026, the stock price increased by over 5.48% to $6.54. Aura Biosciences announced participation in investor conferences on February 25, 2026, and participated in the 8th Annual Evercore Healthcare Conference on November 24, 2025. The previous earnings report on November 13, 2025, was noted as positive. AURA's weekly volatility has been stable, and it has not had significant price volatility compared to the US market.

There is no identifiable demand seasonality for Aura Biosciences, Inc.'s products and services. Demand is likely driven by medical need and regulatory approvals rather than seasonal factors.

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision immunotherapies for solid tumors, particularly in preserving organ function. Their core technology uses virus-like drug conjugates (VDCs) to target and destroy cancer cells while activating the immune system. Their lead product, belzupacap sarotalocan (bel-sar; AU-011), is in late-stage development for primary choroidal melanoma and is also being developed for other ocular oncology indications and bladder cancer.

Aura Biosciences, Inc. primarily operates within the United States, with its corporate office in Cambridge, MA. The company plans to expand into European markets by 2026 to address unmet medical needs in oncology.

Aura Biosciences' brand reputation appears positive, driven by clinical progress and analyst sentiment. Bel-sar received FDA Fast Track designation for early choroidal melanoma and bladder cancer. The company has a consensus rating of "Hold" from analysts, with a significant upside potential in the consensus price target. Positive coverage in articles highlights the company's therapeutic approach and pipeline. The acceleration of Phase 3 trial enrollment and anticipated data readouts contribute positively to its reputation.

Aura Biosciences, Inc. has significant institutional ownership, with 119 institutional owners and shareholders holding 50,167,717 shares as of April 9, 2026, representing 96.75% of the company's stock. Insiders hold 6.30%. Major institutional owners include Matrix Capital Management Company, LP; Frazier Life Sciences Management, L.P.; Adage Capital Partners Gp, L.l.c.; Long Focus Capital Management, Llc; Suvretta Capital Management, Llc; BlackRock, Inc.; Medicxi Ventures Management (Jersey) Ltd; Vanguard Group Inc; Franklin Resources Inc; and Nantahala Capital Management, LLC. Other notable investors include Invesco Ltd., XTX Topco Ltd, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., JPMorgan Chase & Co., and T. Rowe Price Health Sciences Fund, Inc.